KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 106 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q3 2020. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $6,491,640 | +22.9% | 373,721 | -0.4% | 0.00% | 0.0% |
Q2 2023 | $5,281,852 | +30.1% | 375,109 | -0.6% | 0.00% | +100.0% |
Q1 2023 | $4,059,236 | +68887.7% | 377,258 | -4.0% | 0.00% | -50.0% |
Q4 2022 | $5,884 | -99.9% | 392,791 | -0.2% | 0.00% | 0.0% |
Q3 2022 | $5,052,000 | +28.0% | 393,466 | -3.4% | 0.00% | +100.0% |
Q2 2022 | $3,946,000 | +10.0% | 407,147 | +12.8% | 0.00% | 0.0% |
Q1 2022 | $3,588,000 | +91.4% | 360,940 | +126.6% | 0.00% | 0.0% |
Q4 2021 | $1,875,000 | +22.5% | 159,318 | +18.6% | 0.00% | – |
Q3 2021 | $1,530,000 | -66.5% | 134,287 | -59.1% | 0.00% | -100.0% |
Q2 2021 | $4,572,000 | +3.8% | 328,214 | +37.9% | 0.00% | 0.0% |
Q1 2021 | $4,406,000 | +233.0% | 238,047 | +218.0% | 0.00% | – |
Q4 2020 | $1,323,000 | +23.0% | 74,856 | +6.6% | 0.00% | – |
Q3 2020 | $1,076,000 | -35.1% | 70,247 | +7.9% | 0.00% | -100.0% |
Q2 2020 | $1,659,000 | +63.3% | 65,080 | -1.2% | 0.00% | 0.0% |
Q1 2020 | $1,016,000 | +244.4% | 65,871 | +146.8% | 0.00% | – |
Q4 2019 | $295,000 | – | 26,690 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Spearhead Capital Advisors, LLC | 202,580 | $2,601,000 | 2.82% |
Lion Point Capital, LP | 480,000 | $5,140,000 | 1.13% |
HHLR ADVISORS, LTD. | 2,920,023 | $37,493,000 | 0.99% |
TANG CAPITAL MANAGEMENT LLC | 600,000 | $7,704,000 | 0.94% |
Rubric Capital Management LP | 1,446,107 | $18,568,000 | 0.94% |
AlphaCentric Advisors LLC | 43,000 | $552,000 | 0.57% |
RICE HALL JAMES & ASSOCIATES, LLC | 749,933 | $9,629,000 | 0.56% |
Parkman Healthcare Partners LLC | 126,192 | $1,620,000 | 0.46% |
Birchview Capital, LP | 30,000 | $385,000 | 0.27% |
Baker Brothers Advisors | 2,799,577 | $35,947,000 | 0.24% |